Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Accumulated Depreciation (2023 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Accumulated Depreciation for 3 consecutive years, with $175685.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Depreciation rose 22.02% to $175685.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $175685.0, a 22.02% increase, with the full-year FY2024 number at $149433.0, up 0.92% from a year prior.
  • Accumulated Depreciation was $175685.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $149433.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $175685.0 in Q3 2025 to a low of $139650.0 in Q2 2024.
  • A 3-year average of $150881.2 and a median of $148267.5 in 2023 define the central range for Accumulated Depreciation.
  • Peak YoY movement for Accumulated Depreciation: grew 0.92% in 2024, then grew 22.02% in 2025.
  • 60 Degrees Pharmaceuticals' Accumulated Depreciation stood at $148064.0 in 2023, then grew by 0.92% to $149433.0 in 2024, then increased by 17.57% to $175685.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Accumulated Depreciation are $175685.0 (Q3 2025), $149433.0 (Q4 2024), and $143984.0 (Q3 2024).